Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Records Worst Ever Quarterly Loss On Forex Contracts, FDA Action; Rival Cipla Is Going Strong

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Signs of a deepening financial crisis became visible at India's largest drug maker Ranbaxy as it announced its first quarter results with a worst ever recorded quarterly loss of $153 million (761 crore rupees) on sales of $313 million, which fell 4 percent as compared to the same quarter last year
Advertisement

Related Content

Daiichi Sankyo Assumes Complete Control Of Ranbaxy, As Founders Exit
Daiichi Sankyo Assumes Complete Control Of Ranbaxy, As Founders Exit
As Ranbaxy Founders Exit, Daiichi Sankyo Assumes Complete Control; New Management Expects To Resolve U.S. FDA Issue
As Ranbaxy Founders Exit, Daiichi Sankyo Assumes Complete Control; New Management Expects To Resolve U.S. FDA Issue
As Ranbaxy Founders Exit, Daiichi Sankyo Assumes Complete Control; New Management Expects To Resolve U.S. FDA Issue
As Ranbaxy Founders Exit, Daiichi Sankyo Assumes Complete Control; New Management Expects To Resolve U.S. FDA Issue
Ranbaxy In Bear Grip As Sales Slip In U.S. After FDA Restrictions
Ranbaxy In Bear Grip As Sales Slip In U.S. After FDA Restrictions
Advertisement
UsernamePublicRestriction

Register

SC071470

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel